Remepy's hybrid Parkinson's therapy poised for phase 3
Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Pfizer takes 25-valent Prevnar follow-up into phase 3
Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with new data on a 25-valent candidate.
Doctors dismayed by report of NHS AI proposal
The British Medical Association has branded a leaked proposal to rein back NHS recruitment and use more AI to compensate a "massive gamble."
As Ebola deaths climb, search begins for vaccine
The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola and fast-track clinical trials.
GHO, CBC merge to create largest healthcare investment firm
Two top healthcare investors – UK-based GHO and CBC Group of Singapore – have announced a merger to create a massive player in the category.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions